Site‐ and Stage‐Adapted Treatment Strategies for Gastrointestinal Diffuse Large B‐Cell Lymphoma
European Journal of Haematology · 2025
DOI: 10.1111/ejh.14440 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Yu Yagi und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Gastrointestinal Neoplasms. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Although gastrointestinal diffuse large B‐cell lymphoma (GI‐DLBCL) is managed variously, the optimal approach remains controversial.
Methods
We retrospectively analyzed 701 patients with DLBCL at our institution between March 2004 and June 2024, including 160 with GI‐DLBCL. We compared baseline characteristics and survival outcomes of GI‐DLBCL with non‐GI‐DLBCL and further analyzed gastric and intestinal DLBCL by stage.
Results
No significant difference in survival outcomes was observed between GI and non‐GI DLBCL groups after a median follow‐up of 5.1 years. Among patients with gastric DLBCL, advanced disease was associated with poorer overall survival (OS) (hazard ratio [HR]: 1.75; 95% confidence interval [CI]: 1.18–2.58; p = 0.003) than localized disease. Similar findings were observed in intestinal DLBCL (HR: 1.60; 95% CI: 1.13–2.27; p = 0.006). Combined chemoradiation and chemotherapy yielded similar survival outcomes for localized gastric DLBCL although the former showed a higher cumulative incidence of secondary gastric cancer ( p = 0.04). In localized intestinal DLBCL, multivariate analysis identified surgery followed by chemotherapy as a favorable prognostic factor for OS (HR: 0.23; 95% CI: 0.067–0.83; p = 0.024).
Conclusions
Gastrointestinal diffuse large B‐cell lymphoma had survival outcomes comparable to those of non‐GI‐DLBCL, suggesting site‐ and stage‐specific therapies may confer a survival benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Pharmacy, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Radiation Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Gastric Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Colorectal Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
ORCID-Profile: Yusuke Kanemasa
Zitieren
APA
Yagi, Y., Kanemasa, Y., Sasaki, Y., Matsubayashi, M., Yamamura, Y., Fujino, K., Kuga, T., Kanai, N., Masuda, Y., Fujita, K., Ishimine, K., Hayashi, Y., Mino, M., Takahara, A., Tamura, T., Nakamura, S., Okuya, T., Matsuda, S., Shimizuguchi, T., …, & Shimoyama, T. (2025). Site‐ and Stage‐Adapted Treatment Strategies for Gastrointestinal Diffuse Large B‐Cell Lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.14440
Vancouver
Yagi Y, Kanemasa Y, Sasaki Y, Matsubayashi M, Yamamura Y, Fujino K, et al. Site‐ and Stage‐Adapted Treatment Strategies for Gastrointestinal Diffuse Large B‐Cell Lymphoma. European Journal of Haematology. 2025. doi:10.1111/ejh.14440
BibTeX
@article{Yagi2025,
author = {Yagi, Yu and Kanemasa, Yusuke and Sasaki, Yuki and Matsubayashi, Mariko and Yamamura, Yasuhiko and Fujino, Kaho and Kuga, Takahiro and Kanai, Nozomi and Masuda, Yusuke and Fujita, Kumiko and Ishimine, Kento and Hayashi, Yudai and Mino, Mano and Takahara, Ai and Tamura, Taichi and Nakamura, Shohei and Okuya, Toshihiro and Matsuda, Shinichiro and Shimizuguchi, Takuya and Cho, Haruhiko and Kawai, Kazushige and Shimoyama, Tatsu},
title = {Site‐ and Stage‐Adapted Treatment Strategies for Gastrointestinal Diffuse Large B‐Cell Lymphoma},
journal = {European Journal of Haematology},
year = {2025},
doi = {10.1111/ejh.14440}
}
EUVIMED